Treatment outcomes, diagnostic and therapeutic impact: Xpert vs. smear. A systematic review and meta-analysis.

The authors eviewed publications comparing treatment outcomes of drug-susceptible TB patients diagnosed using Xpert vs. smear

From:
Department for International Development
Published
19 March 2019
Document Type:
Journal Article
Theme:
Health
Authors:
Harries, A.D., Takarinda, K.C.

Abstract

Compared with smear microscopy, Xpert® MTB/RIF has the potential to reduce delays in tuberculosis (TB) diagnosis and treatment initiation, and improve treatment outcomes. The authors reviewed publications comparing treatment outcomes of drug-susceptible TB patients diagnosed using Xpert vs. smear.

This research was supported by the UK Department for International Development’s Operational Research Capacity Building Programme led by the International Union Against TB and Lung Disease (The Union)

Citation

Harries AD, Takarinda KC. F1000Prime Recommendation of [Agizew T et al., Int J Tuberc Lung Dis 2019 23(1):82-92]. F1000Prime. 2019. Available from: https://f1000.com/prime/734946505#eval793557528

Treatment outcomes, diagnostic and therapeutic impact: Xpert vs. smear. A systematic review and meta-analysis

Updates to this page

Published 19 March 2019
Contents